Subscribe
shutterstock_1942360891_rafapress
rafapress / Shutterstock.com
18 January 2024BiotechnologySarah Speight

Natera stung for $57m in prenatal screening clash

Dispute centres on genetic prenatal screening methodology | Ravgen’s $57 million award “significantly less” than the $410 million sought by Ravgen | Natera plans to appeal.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Trial-focused: Lead counsel on how a strong story helped Ravgen defeat Natera
25 January 2024   Kerri-Ann Limbeek, trial lead for Ravgen, tells Sarah Speight that a compelling narrative was key to winning the case against their larger rival.
Americas
Natera files patent lawsuit over DNA technology
1 August 2023   The lawsuit alleged the unlawful use of cfDNA technology in RaDaR assay and related products | Adds to an existing legal action the company filed against Inivata.
Medtech
Delaware jury awards $96.3m damages to Natera over kidney transplant tests
30 January 2024   Biotech firm CareDx found to have infringed one of two patents-in-suit through sale of AlloSure and AlloSeq | Damages award consists of $83.6m in lost profits and $12.6m in royalties.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Natera files patent lawsuit over DNA technology
1 August 2023   The lawsuit alleged the unlawful use of cfDNA technology in RaDaR assay and related products | Adds to an existing legal action the company filed against Inivata.
Big Pharma
Trial-focused: Lead counsel on how a strong story helped Ravgen defeat Natera
25 January 2024   Kerri-Ann Limbeek, trial lead for Ravgen, tells Sarah Speight that a compelling narrative was key to winning the case against their larger rival.
Medtech
Delaware jury awards $96.3m damages to Natera over kidney transplant tests
30 January 2024   Biotech firm CareDx found to have infringed one of two patents-in-suit through sale of AlloSure and AlloSeq | Damages award consists of $83.6m in lost profits and $12.6m in royalties.

More on this story

Americas
Natera files patent lawsuit over DNA technology
1 August 2023   The lawsuit alleged the unlawful use of cfDNA technology in RaDaR assay and related products | Adds to an existing legal action the company filed against Inivata.
Big Pharma
Trial-focused: Lead counsel on how a strong story helped Ravgen defeat Natera
25 January 2024   Kerri-Ann Limbeek, trial lead for Ravgen, tells Sarah Speight that a compelling narrative was key to winning the case against their larger rival.
Medtech
Delaware jury awards $96.3m damages to Natera over kidney transplant tests
30 January 2024   Biotech firm CareDx found to have infringed one of two patents-in-suit through sale of AlloSure and AlloSeq | Damages award consists of $83.6m in lost profits and $12.6m in royalties.

More features

Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court
Cooley adds ex-Gowling partner
Apple wins just $250 in Masimo smartwatch clash
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
Big Pharma counsel embrace AI but data and legal risks loom